Home » Autogenomics

Autogenomics

Aug 29, 2017

Prescient Medicine Launches Addiction Risk Test Developed With AutoGenomics

Premium

The company joins others in a still-controversial setting, hoping to market its test to help guide the prescription of narcotic pain medications.

Sep 09, 2016

WuXi to Distribute AutoGenomics' MDx System in China

The companies will also collaborate on new diagnostic technologies and products that are specifically designed for Chinese patients.

Jul 24, 2015

AutoGenomics to Withdraw Planned IPO; Eyes Launch of New MDx Platform in Q1 2016

Premium

The firm will withdraw its planned IPO after being told that it would have to take a 30 to 40 percent discount to its valuation, its CEO said. 

Feb 04, 2015

AutoGenomics Sets Price Range for Planned IPO, Anticipates up to $46.6M in Proceeds

The company said it plans to offer 3.75 million shares of its common stock and expects to fetch between $11 and $13 per share in its IPO.

Oct 08, 2014

AutoGenomics Seeks to Raise $60M in IPO

NEW YORK (GenomeWeb) – Molecular diagnostics firm AutoGenomics has refiled for an initial public offering, less than one year after it pulled earlier plans to go public.

Jul 09, 2014

Genomas, Autogenomics Codeveloping Multiplex Genetic Test for Statin Efficacy and Adverse Events

Premium

Originally published July 8.

Jul 07, 2014

Genomas, AutoGenomics Partner to Advance Dx to Personalize Statin Treatments

NEW YORK (GenomeWeb) – Molecular diagnostics firm AutoGenomics and personalized healthcare company Genomas have signed an agreement to develop genetic tests and DNA-guided diagnostic systems to aid in the selection of statins to improve treatment of heart disease, obesity, and diabetes.

Apr 08, 2014

IP Watch: Epigenomics, Fluidigm, Sony, Life Tech, Others Win US Patents

Premium

Korea Institute of Science and Technology has been awarded

Nov 04, 2013

MDx Firm AutoGenomics Withdraws IPO

NEW YORK (GenomeWeb News) – Molecular diagnostics firm AutoGenomics filed with the US Securities and Exchange Commission to officially withdraw a planned initial public offering.

Sep 04, 2013

Spartan to Continue Talks with FDA as it Aims for Point-of-Care Indication for CYP2C19 Test

Premium

Having garnered 510(k) regulatory clearance in August for its rapid-analysis CYP2C19 genetic test, Spartan Bioscience will continue to work with the US Food and Drug Administration to try to gain the agency's okay for marketing the test in the point-of-care setting.

Pages

The Scan

Double-Blinded Not Preferred Review

Even when given the option, not too many authors choose double-blinded peer-review for their manuscripts, ScienceInsider reports.

This Week in PNAS

In PNAS this week: transcriptional read-through in stressed cells, genome stability role for the epigenetic regulator CTCF, and more.

Grand Trees, Large Genomes

The Save the Redwoods League is teaming with researchers to sequence the genomes of the coast redwood and giant sequoia.

DNA Defense Not Convincing

Two researchers have found that behavioral genetic defenses in criminal cases don't tend to affect outcomes, according to Popular Science.

Sponsorships

Privacy Policy.  Copyright © 2017 GenomeWeb LLC.  All Rights Reserved.